No Difference in Aprepitant vs Fosaprepitant in CINV
This study indicates that there is no difference in efficacy or safety between aprepitant and fosaprepitant, though the study was limited by its small sample size.
HOPA 2017
Facing Ethical Dilemmas in Oncology
Oncology clinicians face ethical dilemmas regarding access to care and treatments, palliative and end-of-life care, and treating vulnerable populations in today’s clinical environment.
Interprofessional Teams To Improve Oncology Care
Interprofessional practice provides benefits to patients, team members, and the health care system, by working collaboratively to support and assist each other.
Nilotinib Associated With Treatment-induced T2DM and Hyperlipidemia
This study suggest that nilotinib is associated with higher rates of treatment-induced T2DM and hyperlipidemia compared with dasatinib.
Four New Drugs Approved for Multiple Myeloma Since 2015
Four new agents were approved for relapsed/refractory multiple myeloma (RRMM) since 2015, providing more options but adding complexity to the treatment of this disease.
Lanreotide Effective Regardless of Prior Octreotide in Carcinoid Syndrome
Lanreotide depot is effective among patients with or without previous octreotide treatment for carcinoid syndrome.
Single-nucleotide Polymorphisms Predict Response to R-CHOP in DLBCL
Two SNPS (rs4880 and rs1870377) had an association with PFS among patients with DLBCL receiving R-CHOP.
Steroid-containing Chemotherapy Can Induce Diabetes in DLBCL
Glucocorticoid-containing chemotherapy may induce diabetes mellitus or worsen glucose control among patients with diffuse large B cell lymphoma.
2016 Oncology Drug Approvals Span Multiple Cancers
At the 2017 HOPA Annual Conference, Vivian Park, PharmD, MBA, BCOP, discussed agents approved by the FDA in oncology in 2016.
Oncology Treatment and Care, The Role of Value-based Frameworks
Multiple value frameworks were developed to help providers, institutions, and payers determine the value of cancer treatment.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in HOPA 2017
Loading... 
Loading...